-
LOCALLY SOURCED
To find and license promising
development candidates from
domestic biotech/pharma com
panies and universities -
REGIONALLY FINANCED
To establish sources of financin
g from regional investment co
mmunities -
GLOBALLY DEVELOPED
To develop assets up to human
PoC(Proof of Concept) globally
Pipeline
We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.
News
[EN]Genexine signs licensing agreement for HyLeukin with I-Mab
Genexine Inc. (KOSDAQ:095700), a clinical stage biotechnology company developing innovative biologics focused on orphan diseases and immuno-oncology, announced that an IND approval of GX-30, recombinant Thyroid-Stimulating Hormone (TSH), was granted a trial of Phase I & II from the Ministry of Food and Drug Safety (MFDS). For thyroid cancer patients, surgery is performed to remove the thyroid g...
Read More-
LEARN MORE ABOUT US
-
CONTACT INFORMATION
HQ: 903-2, 253, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
US Office: Bridge Biotherapeutics, Inc. In JLABS@TMC, John P. McGovern Campus 2450 Holcombe Blvd, HoustonDirector, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)